1.Nicola PA, et al. The somatic mutation landscape of the normal and malignant pancreas. ESMO Congress 2024, Abstract 1O. 2.Gryspeert A-R, et al. Multivariate analysis of functional organoid assays predicts patient resp...
第二项研究中,评估了EGFR–MET双特异性抗体阿米伐单抗联合5-氟尿嘧啶-亚叶酸-奥沙利铂(FOLFOX)或5-氟尿嘧啶-亚叶酸-伊立替康(FOLFIRI)的安全性和疗效。OrigAMI-1 Ib/II期研究共纳入43名RAS/RAF野生型且未接受过EGFR抑制剂的mCRC...
Abstract Title:Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC) -A randomized, open-label, phase III study (ETER100) 研究标题:安罗替尼联合PD-L1抗体贝莫苏拜单抗(TQB2450)对比舒尼替尼一线治疗晚期...
1、Peccatori FA, et al. Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial. ESMO Congress 2024, Abstract 1814O 2、Blondeaux E, et al. Breastfeeding after breast cancer in young BRCA ...
9. Cheng Y, et al. Abstract CT225: Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study[J]. Cancer Res 15 April 2023; 83 (8_Supplement): CT225. ...
2024年欧洲肿瘤内科学会(ESMO)将于9月13日至17日(当地时间)在西班牙巴塞罗那召开,近期已率先公布了大部分摘要标题及其作者信息,但仍有LBA(Late-breaking Abstract)等部分需静待时日。根据已公布的信息显示,乳腺癌领域有多项研究成果将以口头报告的形式亮相,涵盖内容从标准治疗优化(NATALEE研究、HERA研究等)到新药应用探...
其中,呋喹替尼联合斯鲁利单抗用于治疗晚期非透明细胞肾细胞癌的II期研究被选为口头报告;HLX07-NPC201研究数据被接收为LBA(Late-breaking Abstract),由张力教授进行口头报告;HLX07-CSCC201研究结果首次发布于2023 ESMO Asia大会并获评“最佳壁报”奖,此次发布为该研究更新数据。
[7]Yang W, et al.HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms.ESMO 2024.Abstract # 177P 杨文涛 教授 复旦大学附属肿瘤医院病理科副主任,主任医师,博士生导师 中华医学会病理学会乳腺学组组长 第五版世界卫生组织(WHO)乳腺肿瘤分类编委 ...
Abstract Title:Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308) 研究标题:艾帕洛利单抗(Iparomlimab)和托沃瑞利单抗(QL1706)联合贝伐珠单...
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid July 2024, in the section “Information for Presenters”. Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submi...